常山药业：艾本那肽注射液处于审评阶段，能否获批存在不确定性

Core Viewpoint - Changshan Pharmaceutical's stock has experienced significant volatility, with a cumulative increase of 147.69% from May 6 to June 9, 2025, which is substantially higher than the growth of its industry peers and the ChiNext Composite Index [1] Group 1: Stock Performance - The company's stock price has deviated significantly, with a cumulative increase of over 30% in the last two trading days, leading to a classification of abnormal trading activity by the Shenzhen Stock Exchange [1] - The stock's performance has been notably strong, with a total increase of 147.69% over the specified period [1] Group 2: Product Development - The application for the marketing authorization of Aibennate Injection, intended for the treatment of type 2 diabetes, has been accepted by the National Medical Products Administration and is currently under professional review [1] - There are uncertainties regarding the approval of Aibennate Injection for market launch, as there are still many subsequent steps in the review process [1] - The clinical trial application for Aibennate Injection for weight loss indications has also been accepted by the National Medical Products Administration and is under review, with uncertainties surrounding the approval of the clinical trial notification [1]